NCT02166346View on ClinicalTrials.gov

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 8, 2017

Study Completion Date

January 8, 2017

Conditions
Transverse MyelitisNeuromyelitis OpticaIdiopathic Transverse MyelitisMyelitis NOS
Interventions
DRUG

Dalfampridine

Dalfampridine 10 mg twice daily for 8 weeks

DRUG

Placebo

Placebo pill 1 tablet twice daily for 8 weeks

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Acorda Therapeutics
All Listed Sponsors
collaborator

Acorda Therapeutics

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT02166346 - Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) | Biotech Hunter | Biotech Hunter